The CBX6 Knockout HeLa Polyclonal Cells product comprises a heterogeneous population of HeLa cells engineered with CRISPR/Cas9 to disrupt the CBX6 gene, creating a polyclonal loss-of-function model. This format retains genetic diversity while enabling pooled assessment of CBX6-dependent phenotypes, offering a robust tool for epigenetic and cancer research without the clonal bias associated with single-cell isolates.
HeLa cells originate from a human cervical adenocarcinoma and harbor integrated human papillomavirus 18 (HPV18) sequences, which drive constitutive expression of viral oncoproteins E6 and E7. These factors degrade p53 and Rb, respectively, creating a permissive environment for cell cycle progression and malignancy. Widely adopted for studies of tumor biology, HeLa cells exhibit rapid proliferation and well-mapped signaling pathways, making them an informative host for investigating chromatin regulatory mechanisms.
CBX6 functions as a core subunit of Polycomb Repressive Complex 1 (PRC1), where its chromodomain specifically binds trimethylated lysine 27 on histone H3 (H3K27me3), a modification deposited by PRC2 components EZH2 and SUZ12. Through interactions with RING1B, BMI1, and PHC2, CBX6 contributes to chromatin compaction and stable transcriptional silencing. Target genes repressed by CBX6-containing PRC1 include the tumor suppressors CDKN2A and CDH1, linking CBX6 to proliferative control. Upstream, H3K27me3 levels are governed by PRC2 activity and influenced by MYC-driven transcriptional circuits and other chromatin modifiers.
In the HeLa context, disruption of CBX6 perturbs PRC1-mediated gene silencing, offering a platform to dissect how aberrant epigenetic repression contributes to cervical carcinoma progression. Since HeLa cells display altered DNA methylation and histone modification landscapes partially driven by HPV18 oncoproteins, CBX6 knockout allows researchers to separate viral from host epigenetic effects. This model is particularly valuable for studying the interplay between Polycomb-mediated silencing and HPV18-induced transformation, as well as identifying genes that become reactivated upon loss of CBX6 function.
Researchers can apply this CBX6 polyclonal knockout product across a range of experimental workflows. Chromatin immunoprecipitation coupled with quantitative PCR (ChIP-qPCR) enables quantification of H3K27me3 occupancy at known PRC1 target loci, while RT-qPCR and Western blotting verify transcript and protein levels of CBX6, BMI1, and downstream effectors like CDKN2A. RNA sequencing defines global transcriptomic changes, and functional assays??such as colony formation, proliferation, and apoptosis analyses??interrogate the phenotypic consequences of CBX6 loss. Drug target validation studies further benefit from this isogenic background. For further information, please contact Ascent Research.
